Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 12

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 12
---
 hypothesized that the Aethlon
Hemopurifier which contains a propriety GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred
milliliters on donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The
study results showed a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. The results of this
study support the current Australian Clinical Trial in Oncology as well as open the investigation of the Hemopurifier in many indications.

Extracellular vesicles have been
implicated in the pathogenesis of Long COVID. As we had previously demonstrated removal of extracellular vesicles by the Hemopurifier
in a patient with severe acute COVID-19 infection, we hypothesized that patients with Long COVID would have extracellular vesicles with
the mannose sugar on their surface that would bind to the affinity resin in our device. We partnered with investigators at the Univ of
California San Francisco Medical Center Long COVID clinic to obtain samples from participants with Long COVID as well as controls that
had had COVID -10 infection but had recovered. The data to be presented will review the binding of larger and smaller extracellular vesicles
to the GNA lectin and the lectin affinity resin, respectively. We believe the data from this pre-clinical study calls for additional study
of the Hemopurifier and look forward to receiving feedback from the Long COVID scientific community at the Keystone Symposium.

Successful outcomes of human trials
will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some
of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment
technology.

In addition to the foregoing,
we are monitoring closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts
in Israel and the surrounding areas, as well as related political and economic responses and counter-responses by various global factors
on our business. Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy,
we are unable to assess the impact on our timelines and future access to capital. The full